Key result
The combination of uric acid > 8.0 mg/dL and NT-ProBNP > 4,210 pg/mL significantly increased the risk of short-term cardiovascular events in patients with acute heart failure (HR 5.840).
Why the study?
Does the combination of uric acid and NT-ProBNP levels predict short-term cardiovascular events in patients with acute heart failure?
Cohort (n=193)
No
Does the combination of uric acid and NT-ProBNP levels predict short-term cardiovascular events in patients with acute heart failure?
Hazard Ratio: 5.84 (95% CI 1.677–20.333)
p-value: p=0.006
May aid short-term risk stratification in acute HF; leaves open need for prospective validation before clinical adoption.
BACKGROUND/AIMS: In patients with heart failure (HF), N-terminal prohormone brain natriuretic peptide (NT-ProBNP) is a standard prognostic indicator. In addition, uric acid (UA) was recently established as a prognostic marker for poor outcome in chronic HF. The aim of this study was to determine the combined role of UA and NT-ProBNP as prognostic markers for short-term outcomes of acute heart failure (AHF). METHODS: The levels of UA and NT-ProBNP were determined in 193 patients (age, 69 ± 13 years; 76 males) admitted with AHF. Patients were followed for 3 months and evaluated for cardiovascular events, defined as cardiac death and/or readmission for HF. RESULTS: Of the 193 patients, 23 (11.9%) died and 20 (10.4%) were readmitted for HF during the 3-month follow-up period. Based on univariate analysis, possible predictors of short-term cardiovascular events were high levels of UA and NT-ProBNP, low creatinine clearance, no angiotensin converting enzyme inhibitors or angiotensin receptor blockers, and old age. Multivariate Cox hazard analysis showed that UA levels were independently associated with increased incidence of cardiovascular events (hazard ratio, 1.115; 95% confidence interval, 1.006 to 1.235; p = 0.037). Kaplan-Meier survival analysis revealed that patients with UA levels > 8.0 mg/dL and NT-ProBNP levels > 4,210 pg/mL were at highest risk for cardiac events (p = 0.01). CONCLUSIONS: The combination of UA and NT-ProBNP levels appears to be more useful than either marker alone as an independent predictor for short-term outcomes in patients with AHF.
No takes yet. Share an insight, caveat, or question.
Park et al. (2010) conducted a cohort in Acute heart failure (n=193). Combination of Uric Acid > 8.0 mg/dL and NT-ProBNP > 4,210 pg/mL vs. Uric Acid ≤ 8.0 mg/dL and NT-ProBNP ≤ 4,210 pg/mL was evaluated on Cardiovascular events (cardiovascular death and/or readmission for heart failure within 3 months) (HR 5.840, 95% CI 1.677-20.333, p=0.006). The combination of uric acid > 8.0 mg/dL and NT-ProBNP > 4,210 pg/mL significantly increased the risk of short-term cardiovascular events in patients with acute heart failure (HR 5.840).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: